MedTrace Logo

Colesevelam, Lipids And Sugars, South Asian Canadian Trial

NCT02504736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2020-01-23

No results posted yet for this study

Summary

To evaluate the effect of colesevelam on LDL levels and A1c in high-risk , dysglycemic South Asians (with diabetes, and/or with CAD and concomitant metabolic syndrome) whose LDL remains above target despite optimal statin use.

Conditions

Sponsors & Collaborators

  • Valeant Canada Limited

    collaborator INDUSTRY

  • Canadian Collaborative Research Network

    lead OTHER

Principal Investigators

  • Milan K Gupta, MD · McMaster University, Hamilton, ON Canada; University of Toronto, Toronto, ON Canada

  • Narendra Singh, MD · Georgia Regents University, Georgia, US

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-02-15
Completion
2018-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504736 on ClinicalTrials.gov